Since 2000, the annual Work Plan of the Office of the Inspector General (OIG) listed clinical research and clinical trials as a compliance target. As a result, sponsors, investigators, and institutions have increased their vigilance over the operation of clinical research activities. Have those efforts been in the right direction? Have they been enough?
This session will focus on learning the perspective, understanding the actions, and preparing to respond to the OIG’s position and priorities.
Presenters
- William Moran is the recently retired regional inspector general for the U.S. Department of Health & Human Services, Region V. Mr. Moran currently is a vice president with the Chicago office of Strategic Management Systems, Inc.
- LaDale K. George is a partner with Foley’s Health Care Industry Team and is the leader of the Translational Research Focus Group.
Related Insights
April 15, 2026
The Path & The Practice
Episode 134: Jesse Neil, Partner
This episode features a conversation with Jesse Neil. Jesse is a healthcare attorney in Foley’s Nashville office. In this discussion, he reflects on growing-up in Nashville, TN, attending the University of North Carolina at Chapel Hill for undergrad and the University of Mississippi School of Law.
April 15, 2026
Foley Viewpoints
Key Health Care Enforcement Trends Under the Trump Administration: FCA, Data Analytics, and Emerging Risk Areas
These trends included (i) an enduring focus on waste, fraud, and abuse in the health care industry; (ii) a continued focus on Medicare Advantage and a newer focus on gender transition procedures for minors; and (iii) the ever-increasing use of data analytics to prosecute cases.
April 14, 2026
Health Care Law Today
FDA Clarifies Policies for Pharmacy Compounders of GLP-1 Products
On April 1, 2026,the U.S. Food & Drug Administration (FDA) issued a statement clarifying its compliance policy on the conditions that must be met for compounded drugs to qualify for the exemptions under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act).